Priothera Appoints New Chief Medical Officer
Priothera Ltd., a pioneering late-stage biopharma company, has recently appointed Dr. Jens Hasskarl as its Chief Medical Officer. Dr. Hasskarl, a distinguished medical professional with extensive experience in clinical development, will lead the exciting Phase 3 clinical study known as MO-TRANS. This global investigation focuses on mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, aiming to enhance treatment options for patients battling acute myeloid leukemia (AML).
Dr. Hasskarl's Impressive Background
With over 20 years of leadership experience in the biotech and pharmaceutical sectors, Dr. Hasskarl has a proven track record in clinical research, translational science, and medical affairs. Prior to joining Priothera, he served as CMO at Advesya AG, where he spearheaded the development of innovative immunotherapies targeting hematologic conditions and autoimmune diseases. Dr. Hasskarl's previous positions at renowned companies such as Tigen Pharma, Celgene, and Novartis equipped him with vital insights into the development and global launch of multiple cellular therapies.
Leadership Views on the Appointment
Florent Gros, co-founder and CEO of Priothera, expressed his enthusiasm about the appointment, stating, "Jens’ deep expertise in hematology, cellular therapy, and drug development provides us with valuable leadership as we advance towards the final phases of clinical execution for mocravimod." He emphasized the importance of Dr. Hasskarl's role in guiding the company through pivotal stages in gaining regulatory approval and effectively bringing the therapy to market.
Dr. Hasskarl’s Vision for the Future
Dr. Hasskarl himself shared his excitement about joining Priothera. He stated, "I am thrilled to join Priothera during such an exciting phase. The company’s dedication to scientific excellence and focus on improving outcomes for AML patients align perfectly with my passion for advancing innovation in hematology." His commitment and enthusiasm signal a bright outlook for Priothera as the company moves forward.
Understanding Mocravimod
Mocravimod, also known as KRP203, is at the forefront of gastrointestinal and hematologic malignancy treatment. Designed to be a synthetic S1P receptor modulator, it aims to enhance the effectiveness of allogeneic hematopoietic cell transplantation (allo-HCT) while minimizing the risks typically associated with graft-versus-host disease (GvHD). This innovative approach positions mocravimod as a unique therapy that preserves the essential graft-versus-leukemia (GvL) effect necessary for eliminating cancer cells.
Looking Ahead: Priothera's Mission
Priothera is steadfast in its mission to establish mocravimod as a potential new standard of care for those suffering from hematologic cancers. By focusing on integrating mocravimod with existing cellular therapies and allo-HCT, the company aims to reshape the treatment landscape for AML and other blood cancers. With a strong foundation laid since its establishment in 2020, Priothera combines the expertise of its top-tier management team and continuous backing from prominent life sciences investors.
Staying Informed About Priothera
For those interested in learning more about Priothera and its groundbreaking work with mocravimod, updates and additional information can be found on their official website or their LinkedIn profile. This dynamic company is set to make significant waves in the treatment of acute myeloid leukemia, continuing to drive forward with passion and dedication.
Frequently Asked Questions
What role will Dr. Jens Hasskarl fulfill at Priothera?
Dr. Hasskarl will serve as the Chief Medical Officer and oversee the Phase 3 MO-TRANS clinical study for mocravimod as a treatment for AML.
What is mocravimod?
Mocravimod is a synthetic S1P receptor modulator being developed to enhance the treatment of AML, particularly as an adjunct to allo-HCT.
How does Priothera plan to improve outcomes for AML patients?
Priothera aims to improve patient outcomes by leveraging mocravimod in conjunction with traditional therapies, focusing on safety and efficacy.
What was Dr. Hasskarl's experience before joining Priothera?
Dr. Hasskarl has served various executive roles in leading biotech firms, focusing on clinical development in hematology and immunotherapy.
How does mocravimod work in the treatment of AML?
Mocravimod works by maintaining the graft-versus-leukemia effect while mitigating risks associated with graft-versus-host disease, aiming to enhance treatment safety and effectiveness.
